Kestra Medical Technologies (NASDAQ:KMTS) Insider Timothy Moran Sells 3,192 Shares of Company Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Timothy Moran sold 3,192 shares of the firm’s stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $29.56, for a total transaction of $94,355.52. Following the completion of the sale, the insider owned 63,153 shares in the company, valued at $1,866,802.68. This represents a 4.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Down 6.5%

Shares of NASDAQ:KMTS opened at $28.53 on Friday. The company has a fifty day moving average of $26.90 and a 200-day moving average of $23.96. The company has a market capitalization of $1.70 billion, a PE ratio of -10.69 and a beta of 0.45. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.69 and a current ratio of 4.69. Kestra Medical Technologies, Ltd. has a 52-week low of $17.34 and a 52-week high of $31.91.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings results on Monday, September 14th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.14). Kestra Medical Technologies had a negative net margin of 140.43% and a negative return on equity of 63.83%. The firm had revenue of $30.97 million during the quarter. On average, equities analysts predict that Kestra Medical Technologies, Ltd. will post -2.45 EPS for the current fiscal year.

Institutional Trading of Kestra Medical Technologies

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Corient Private Wealth LP grew its position in shares of Kestra Medical Technologies by 284.2% in the 2nd quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock valued at $1,542,000 after buying an additional 44,839 shares during the last quarter. Sei Investments Co. increased its stake in shares of Kestra Medical Technologies by 22.6% in the first quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock valued at $4,726,000 after buying an additional 43,753 shares during the period. Spartan Wealth Advisory Services LLC acquired a new stake in shares of Kestra Medical Technologies in the first quarter valued at about $603,000. Bank of New York Mellon Corp raised its position in shares of Kestra Medical Technologies by 47.2% during the first quarter. Bank of New York Mellon Corp now owns 70,113 shares of the company’s stock worth $1,397,000 after acquiring an additional 22,471 shares during the last quarter. Finally, Quantinno Capital Management LP bought a new position in shares of Kestra Medical Technologies during the first quarter worth about $431,000.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. Evercore initiated coverage on Kestra Medical Technologies in a research report on Tuesday, October 20th. They issued an “outperform” rating and a $34.00 target price for the company. BTIG Research restated a “buy” rating and set a $32.00 price target on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Royal Bank Of Canada set a $30.00 price objective on Kestra Medical Technologies in a research note on Tuesday, September 15th. Wolfe Research set a $30.00 price objective on shares of Kestra Medical Technologies in a report on Wednesday, July 15th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Kestra Medical Technologies in a research report on Monday, August 10th. They set an “overweight” rating and a $30.00 target price on the stock. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $29.00.

Kestra Medical Technologies Company Profile

Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient’s heart rhythm and deliver a therapeutic shock when clinically necessary.

The company’s platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.